Lu, Jin
Sun, Jiangwen
Wang, Xinyu
Kranzler, Henry
Gelernter, Joel
Bi, Jinbo
Article History
First Online: 22 November 2018
Ethics approval and consent to participate
: This work is a secondary analysis of existing datasets collected in prior multi-site studies. In those studies, the institutional review board (IRB) at each site approved their study protocol and informed consent forms. The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism each provided a Certificate of Confidentiality to protect participants. The secondary analysis in the present article has been reviewed and approved by the IRB of the University of Connecticut with a protocol number H15-045.
: This work presents a population-level analysis using de-identified existing data. The IRB of the University of Connecticut has determined that a consent to publication from original study participants is not needed.
: Dr. Kranzler has been an advisory board member, consultant, or CME speaker for Alkermes, Indivior and Lundbeck. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.